MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro
Renal fibrosis is a common pathological feature of various kidney diseases, leading to irreversible renal failure and end-stage renal disease. However, there are still no effective treatments to reverse renal fibrosis. This study aimed to explore the potential mechanism of a targeted drug for fibros...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/11/21/3505 |
| _version_ | 1827646939845361664 |
|---|---|
| author | Meiling Chen Yihang Yu Tao Mi Qitong Guo Bin Xiang Xiaomao Tian Liming Jin Chunlan Long Lianju Shen Xing Liu Jianbo Pan Yuanyuan Zhang Tao Xu Deying Zhang Guanghui Wei |
| author_facet | Meiling Chen Yihang Yu Tao Mi Qitong Guo Bin Xiang Xiaomao Tian Liming Jin Chunlan Long Lianju Shen Xing Liu Jianbo Pan Yuanyuan Zhang Tao Xu Deying Zhang Guanghui Wei |
| author_sort | Meiling Chen |
| collection | DOAJ |
| description | Renal fibrosis is a common pathological feature of various kidney diseases, leading to irreversible renal failure and end-stage renal disease. However, there are still no effective treatments to reverse renal fibrosis. This study aimed to explore the potential mechanism of a targeted drug for fibrosis. Here, unilateral ureteral obstruction (UUO)-treated mice and a TGF-β1-treated human renal tubular epithelial cell line (HK-2 cells) were used as models of renal fibrosis. Based on the changes of mRNA in UUO kidneys detected by transcriptome sequencing, MK-2206, an Akt inhibitor, was predicted as a potential drug to alleviate renal fibrosis through bioinformatics. We dissolved UUO mice with MK-2206 by gastric gavage and cultured TGF-β-induced HK-2 cells with MK-2206. Histopathological examinations were performed after MK-2206 intervention, and the degree of renal fibrosis, as well as the expression of Akt/mTOR pathway-related proteins, were evaluated by immunohistochemical staining, immunofluorescence staining, and Western blot. The results showed that MK-2206 significantly improved the pathological structure of the kidney. Furthermore, MK-2206 intervention effectively inhibited UUO- and TGF-β1-induced epithelial-mesenchymal transition, fibroblast activation, and extracellular matrix deposition. Mechanistically, MK-2206 treatment attenuated the activation of the Akt/mTOR signaling pathway. Taken together, our study revealed for the first time that MK-2206 is a promising drug for the improvement of renal fibrosis. |
| first_indexed | 2024-03-09T19:11:26Z |
| format | Article |
| id | doaj.art-84f1659a8fab47bbb99071fbddbba708 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-09T19:11:26Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-84f1659a8fab47bbb99071fbddbba7082023-11-24T04:09:52ZengMDPI AGCells2073-44092022-11-011121350510.3390/cells11213505MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In VitroMeiling Chen0Yihang Yu1Tao Mi2Qitong Guo3Bin Xiang4Xiaomao Tian5Liming Jin6Chunlan Long7Lianju Shen8Xing Liu9Jianbo Pan10Yuanyuan Zhang11Tao Xu12Deying Zhang13Guanghui Wei14Department of Urology, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing 400014, ChinaDepartment of Urology, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing 400014, ChinaDepartment of Urology, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing 400014, ChinaDepartment of Urology, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing 400014, ChinaDepartment of Urology, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing 400014, ChinaDepartment of Urology, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing 400014, ChinaDepartment of Urology, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing 400014, ChinaDepartment of Urology, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing 400014, ChinaDepartment of Urology, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing 400014, ChinaDepartment of Urology, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing 400014, ChinaCenter for Novel Target and Therapeutic Intervention, Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, ChinaWake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27101, USABiomanufacturing Center, Department of Mechanical Engineering, Tsinghua University, Beijing 100084, ChinaDepartment of Urology, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing 400014, ChinaDepartment of Urology, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing 400014, ChinaRenal fibrosis is a common pathological feature of various kidney diseases, leading to irreversible renal failure and end-stage renal disease. However, there are still no effective treatments to reverse renal fibrosis. This study aimed to explore the potential mechanism of a targeted drug for fibrosis. Here, unilateral ureteral obstruction (UUO)-treated mice and a TGF-β1-treated human renal tubular epithelial cell line (HK-2 cells) were used as models of renal fibrosis. Based on the changes of mRNA in UUO kidneys detected by transcriptome sequencing, MK-2206, an Akt inhibitor, was predicted as a potential drug to alleviate renal fibrosis through bioinformatics. We dissolved UUO mice with MK-2206 by gastric gavage and cultured TGF-β-induced HK-2 cells with MK-2206. Histopathological examinations were performed after MK-2206 intervention, and the degree of renal fibrosis, as well as the expression of Akt/mTOR pathway-related proteins, were evaluated by immunohistochemical staining, immunofluorescence staining, and Western blot. The results showed that MK-2206 significantly improved the pathological structure of the kidney. Furthermore, MK-2206 intervention effectively inhibited UUO- and TGF-β1-induced epithelial-mesenchymal transition, fibroblast activation, and extracellular matrix deposition. Mechanistically, MK-2206 treatment attenuated the activation of the Akt/mTOR signaling pathway. Taken together, our study revealed for the first time that MK-2206 is a promising drug for the improvement of renal fibrosis.https://www.mdpi.com/2073-4409/11/21/3505chronic kidney diseasesrenal fibrosisMK-2206Akt/mTOR signaling pathway |
| spellingShingle | Meiling Chen Yihang Yu Tao Mi Qitong Guo Bin Xiang Xiaomao Tian Liming Jin Chunlan Long Lianju Shen Xing Liu Jianbo Pan Yuanyuan Zhang Tao Xu Deying Zhang Guanghui Wei MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro Cells chronic kidney diseases renal fibrosis MK-2206 Akt/mTOR signaling pathway |
| title | MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro |
| title_full | MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro |
| title_fullStr | MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro |
| title_full_unstemmed | MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro |
| title_short | MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro |
| title_sort | mk 2206 alleviates renal fibrosis by suppressing the akt mtor signaling pathway in vivo and in vitro |
| topic | chronic kidney diseases renal fibrosis MK-2206 Akt/mTOR signaling pathway |
| url | https://www.mdpi.com/2073-4409/11/21/3505 |
| work_keys_str_mv | AT meilingchen mk2206alleviatesrenalfibrosisbysuppressingtheaktmtorsignalingpathwayinvivoandinvitro AT yihangyu mk2206alleviatesrenalfibrosisbysuppressingtheaktmtorsignalingpathwayinvivoandinvitro AT taomi mk2206alleviatesrenalfibrosisbysuppressingtheaktmtorsignalingpathwayinvivoandinvitro AT qitongguo mk2206alleviatesrenalfibrosisbysuppressingtheaktmtorsignalingpathwayinvivoandinvitro AT binxiang mk2206alleviatesrenalfibrosisbysuppressingtheaktmtorsignalingpathwayinvivoandinvitro AT xiaomaotian mk2206alleviatesrenalfibrosisbysuppressingtheaktmtorsignalingpathwayinvivoandinvitro AT limingjin mk2206alleviatesrenalfibrosisbysuppressingtheaktmtorsignalingpathwayinvivoandinvitro AT chunlanlong mk2206alleviatesrenalfibrosisbysuppressingtheaktmtorsignalingpathwayinvivoandinvitro AT lianjushen mk2206alleviatesrenalfibrosisbysuppressingtheaktmtorsignalingpathwayinvivoandinvitro AT xingliu mk2206alleviatesrenalfibrosisbysuppressingtheaktmtorsignalingpathwayinvivoandinvitro AT jianbopan mk2206alleviatesrenalfibrosisbysuppressingtheaktmtorsignalingpathwayinvivoandinvitro AT yuanyuanzhang mk2206alleviatesrenalfibrosisbysuppressingtheaktmtorsignalingpathwayinvivoandinvitro AT taoxu mk2206alleviatesrenalfibrosisbysuppressingtheaktmtorsignalingpathwayinvivoandinvitro AT deyingzhang mk2206alleviatesrenalfibrosisbysuppressingtheaktmtorsignalingpathwayinvivoandinvitro AT guanghuiwei mk2206alleviatesrenalfibrosisbysuppressingtheaktmtorsignalingpathwayinvivoandinvitro |